Reply

Annals of Neurology

Volumn 69, Issue 2, 2011, Pages 430-431

  Major, Eugene O ^a   Ryschkewitsch, Caroline F ^a   Jensen, Peter N ^a   Monaco, Maria Chiara ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ANTIBODY;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JC VIRUS; LETTER; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIREMIA; IMMUNOLOGY;

ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; JC VIRUS;

EID: 79952497784     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22364     Document Type: Letter

References (4)

1. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO,. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2009; 68: 384-391.
2. Viscidi RP, Rollison DE, Viscidi E, et al. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 2003; 10: 278-285. (Pubitemid 36314453)
3. Kean J, Rao S, Wang M, Garcea R,. Seroepidemiology of human polyomoaviruses. PloS Pathog 2009; 5: 1-9.
4. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies; implications for PML risk stratification. Ann Neurol 2009; 68: 295-303.